AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

The healthcare sector is shifting as legacy blockbusters face competition from low-cost generics while new chronic care treatments explode. Choosing between AbbVie Inc (NYSE:ABBV) and Novo Nordisk A/S (NYSE:NVO) requires weighing diversification against specialized growth.

AbbVie is a broad biopharmaceutical giant with a diverse lineup of immunology and oncology drugs. Novo Nordisk focus is narrower, leading the world in metabolic health through its diabetes and obesity therapies. Both are high-profile pharmaceutical stocks, but they offer very different risk and reward profiles for retail investors.

The case for AbbVie

AbbVie functions as a diversified pharmaceutical company that develops and sells therapies for immunology, oncology, and aesthetics. Its primary customers include hospitals, government agencies, and specialty pharmacies, though its U.S. sales are concentrated among three major wholesale distributors. McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH), and Cencora Inc (NYSE:COR) represent significant distribution partners, and customer concentration like this adds a layer of risk to the business.

In FY 2025, revenue reached $61.2 billion, representing revenue growth of just about 8.7% compared to the previous year. The company reported net income of $4.2 billion for the same period. This resulted in a net margin around 7%, which measures how much of each dollar in revenue is kept as profit after all expenses are paid.

As of its December 2025 balance sheet, the debt-to-equity ratio is negative 21x, indicating that total liabilities exceed shareholder equity. The so-called current ratio is 0.7x, which suggests the company has $0.70 in short-term assets for every dollar of short-term debt. Free cash flow totaled $17.8 billion in FY 2025, which is the cash left over after paying for operations and purchasing equipment or other assets.

The case for Novo Nordisk

Novo Nordisk A/S focuses its strategy on chronic disease care, specifically in the areas of diabetes and obesity. The company serves more than 45 million people worldwide and operates production sites across multiple continents, including North America and Europe. Unlike many of its peers, the company does not disclose specific major customer concentrations in its latest filings, suggesting a more fragmented customer base.

In FY 2025, revenue reached $48.2 billion (the company reports in Danish kroner; the figures have been converted to U.S. dollars), an increase of more than 6% over the prior year. Net income for the year was nearly $16 billion, which is the total profit remaining after all costs and taxes. This performance resulted in a net margin of 33%, showing that the company retains a high percentage of its sales as profit.

As of its December 2025 balance sheet, the debt-to-equity ratio is 0.7x. This means the company holds roughly $0.70 of debt for every dollar of equity held by shareholders. Novo's current ratio is 0.8x, and free cash flow for the year reached approximately $4.5 billion. Free cash flow is a critical measure of the cash a company generates after accounting for the money spent to maintain or expand its asset base.

Risk profile comparison

AbbVie faces significant risks from patent expirations and the introduction of generic competition for Humira, its former top-selling drug. Revenue is increasingly concentrated in two newer drugs, Skyrizi and Rinvoq, which combined for approximately 42% of total sales in 2025. Additionally, the company is managing pricing pressure from the Inflation Reduction Act and the high failure rate inherent in developing new pharmaceutical therapies.

Novo Nordisk A/S operates in a highly competitive market where manufacturing capacity and supply chain efficiency are constant challenges. The company must navigate intense competition from other drug manufacturers and potential pricing regulations on insulin and weight-loss medications. Furthermore, the company faces risks related to the clinical trial process, where unexpected side effects or a lack of efficacy could prevent new treatments from reaching the market.

Valuation comparison

Novo Nordisk A/S currently trades at lower multiples than AbbVie, suggesting a more conservative valuation relative to its future earnings estimates and annual sales.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

AbbVie has a drug pipeline that some on Wall Street believe could include blockbusters (more than $1 billion in lifetime revenue) for treating schizophrenia, Parkinson's disease, psychosis from Alzheimer's, and certain solid tumors.

On top of that, the business is buying itself additional growth with its recent deal to acquire Apogee Therapeutics. Its two relatively new immunology products, Skyrizi and Rinvoq, have proven to be true growth drivers for the business, and investors are hopeful that an FDA decision on a Parkinson's treatment later this year will bode well for the company. AbbVie is expected to see screaming growth in net income this year, from $4.2 billion to $14.6 billion. Sales should grow to $67.2 billion.

Novo Nordisk, meanwhile, has the blockbuster drugs Wegovy and Ozempic (the same drug marketed for different purposes) but faces investor doubts about its market position given a deal with the federal government to lower prices for the GLP-1s, the emergence of generic competitors, and the apparent advances by Eli Lilly & Co (NYSE:LLY) in developing weight loss drugs expected to be superior to Novo's offerings.

Still, the introduction of the once a day Wegovy pill in the U.S. has been a resounding success and the business has a patent on injectable Ozempic/Wegovy till 2032, providing it some competitive moat. Still, Wall Street sees sales declining in fiscal 2026 by about 3% with net income contracting 4% as pricing pressures erode margins just a bit. Longer-term, analysts expect the company to reverse the 2026 decline and start growing again as new products come on line.

It's hard to say don't buy the company that invented the GL-1 market, but AbbVie's near-term, growth is so impressive it is worth paying the slightly pricier premiums on its P/S and forward P/E ratios and waiting to see how Novo Nordisk adjusts to heightened competition.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Eli Lilly, and Novo Nordisk. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.